CMMB Chemomab Therapeutics
- 1.430
- -0.005-0.35%
Chemomab Therapeutics News
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(9.99%),OrbiMed Israel GP Ltd.(9.99%), etc.
Chemomab Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Chemomab Therapeutics | 424B3: Prospectus
Chemomab Therapeutics | EFFECT: Others
Chemomab Therapeutics | CORRESP: CORRESP
Chemomab Therapeutics | UPLOAD: Others
Chemomab Therapeutics | F-3: Registration statement for specified transactions by certain foreign private issuers
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Chemomab Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sphera Funds Management Ltd.(6.56%),Sphera Global Healthcare GP Ltd.(6.56%), etc.
Chemomab Therapeutics | D: Filing D
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Chemomab Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Chemomab Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Chemomab Therapeutics | 20-F: FY2023 Annual Report
Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(16.0%),OrbiMed Israel GP Ltd.(16.0%), etc.
Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Chemomab Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Analysis
Price Target
No Data
No Data